Nick Roberts Acquires 117 Shares of Diaceutics (LON:DXRX) Stock

Diaceutics PLC (LON:DXRX) insider Nick Roberts acquired 117 shares of Diaceutics stock in a transaction that occurred on Tuesday, December 23rd. The stock was acquired at an average price of GBX 128 per share, with a total value of £149.76.

Nick Roberts also recently made the following trade(s):

• On Wednesday, October 1st, Nick Roberts bought 91 shares of Diaceutics stock. The shares were bought at an average cost of GBX 165 per share, with a total value of £150.15.

Diaceutics Price Performance

DXRX stock opened at GBX 129 on Thursday. The firm has a 50 day moving average of GBX 152.26 and a 200-day moving average of GBX 142.27. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of £109.17 million, a P/E ratio of -71.67 and a beta of 0.58. Diaceutics PLC has a 12 month low of GBX 106 and a 12 month high of GBX 168.

Diaceutics (LON:DXRX) last posted its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (2.84) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. As a group, sell-side analysts predict that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.